health
February 9, 2026
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.
TL;DR
- The FDA has identified "false or misleading" claims in Novo Nordisk's TV advertisement for the obesity pill Wegovy.
- The agency stated the ad implies superior benefits and broader life solutions beyond weight loss, which are not supported by evidence.
- The advertisement also allegedly failed to properly present risk information.
- The FDA has requested that Novo Nordisk take immediate action to address these violations, potentially including ceasing the misleading ads.
- Novo Nordisk has confirmed receipt of the FDA letter and is working to address the concerns.
- This issue adds to the challenges Novo Nordisk faces in the GLP-1 market, including competition from Eli Lilly and compounded copycats.
- Novo Nordisk is also suing Hims & Hers for mass marketing compounded versions of Wegovy.
Continue reading the original article